Home » Stocks » CHEK

Check-Cap Ltd. (CHEK)

Stock Price: $1.41 USD -0.12 (-7.84%)
Updated Feb 25, 2021 4:00 PM EST - Market closed
Pre-market: $1.34 -0.07 (-4.97%) Feb 26, 8:09 AM
Market Cap 68.89M
Revenue (ttm) n/a
Net Income (ttm) -13.84M
Shares Out 7.99M
EPS (ttm) -0.66
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day February 25
Last Price $1.41
Previous Close $1.53
Change ($) -0.12
Change (%) -7.84%
Day's Open 1.49
Day's Range 1.37 - 1.56
Day's Volume 2,967,285
52-Week Range 0.24 - 2.93

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 4 weeks ago

The technology appears safe, but performance versus standard of care requires a larger, expensive study. It will take a couple years to get readouts from the pivotal US study, providing a lack...

InvestorPlace - 1 month ago

Check-Cap Ltd. (CHEK) stock is on the rise Monday despite a lack of news from the maker of the C-Scan colorectal cancer screening device.

Zacks Investment Research - 5 months ago

CheckCap Ltd. (CHEK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

PRNewsWire - 7 months ago

ISFIYA, Israel, July 23, 2020 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the developme...

Zacks Investment Research - 8 months ago

CheckCap Ltd. (CHEK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

PRNewsWire - 8 months ago

ISFIYA, Israel, June 5, 2020 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), a clinical-stage medical diagnostics company advancing the development of C-ScanĀ®, th...

PRNewsWire - 8 months ago

ISFIYA, Israel, May 27, 2020 /PRNewswire/ -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK) (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the developmen...

Zacks Investment Research - 9 months ago

CheckCap Ltd. (CHEK) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

Zacks Investment Research - 10 months ago

Check-Cap Ltd. (CHEK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Benzinga - 1 year ago

Check-Cap announced positive final results from its recently completed post-CE approval study evaluating the clinical performance and safety of the C-Scan system.

About CHEK

Check-Cap, a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, whic... [Read more...]

Industry
Diagnostics & Research
IPO Date
Feb 19, 2015
CEO
Guy Neev
Employees
64
Stock Exchange
NASDAQ
Ticker Symbol
CHEK
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to one analyst, the rating for Check-Cap stock is "Buy" and the 12-month stock price forecast is 1.75.

Price Target
$1.75
Analyst Consensus: Buy